eFFECTOR Therapeutics, Inc.

eFFECTOR Therapeutics, Inc. (Nasdaq: EFTR) is a clinical-stage biopharmaceutical company operating in the oncology sector, focused on the development of selective translation regulator inhibitors targeting cancer pathways. The company became publicly traded in 2021 through a business combination with Locust Walk Acquisition Corp., a blank-check vehicle sponsored by Locust Walk Partners following the SPAC's 2020 initial public offering. On February 24, 2022, eFFECTOR filed an 8-K current report with the SEC, disclosing a material corporate event in accordance with its exchange reporting obligations. For complete filing history, sponsor intelligence, and deal analytics covering EFTR and the broader SPAC market, create a free account at SpacDesk.